Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Laura Pierson - Investor Relations Jack Phillips - President & Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated 2023 Q1 Results Conference Call. All participants will be in listen-only mode.

Accelerate Diagnostics, Inc. (AXDX) Q1 2023 Earnings Call Transcript

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.25 per share a year ago.

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

TUCSON, Ariz. , May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.

Accelerate Diagnostics Reports First Quarter 2023 Financial Results

TUCSON, Ariz. , April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2023 first quarter results

Accelerate Diagnostics (AXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Laura Pierson - IR Jack Phillips - President and CEO Steve Reichling - outgoing-CFO David Patience - incoming-CFO Conference Call Participants Alex Nowak - Craig-Hallum Dustin Scaringe - William Blair Operator Good afternoon, and welcome to the Accelerate Diagnostics Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Accelerate Diagnostics, Inc. (AXDX) Q4 2022 Earnings Call Transcript

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 12.50% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates

TUCSON, Ariz. , March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.

Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results

TUCSON, Ariz. , March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results

TUCSON, Ariz. , March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023.

Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement

TUCSON, Ariz. , March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023.

Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

TUCSON, Ariz. , Dec. 19, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit.

Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit

Boston, Massachusetts--(Newsfile Corp. - November 15, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost money in their Accelerate Diagnostics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/axdx.What is this all about?After the market closed on October 21, 2022, Accelerate Diagnostics, Inc. disclosed receiving a request from the U.S.

Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Laura Pierson - IR Officer Jack Phillips - CEO, President & Director Steve Reichling - CFO Conference Call Participants Andrew Brackmann - William Blair & Company Connor Stevenson - Craig-Hallum Operator Good afternoon, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2022 Earnings Call. [Operator Instructions].

Accelerate Diagnostics, Inc. (AXDX) Q3 2022 Earnings Call Transcript

TUCSON, Ariz. , Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022.

Accelerate Diagnostics Reports Third Quarter 2022 Financial Results

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate" or the "Company") (NASDAQ: AXDX).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ: AXDX) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

Los Angeles, California--(Newsfile Corp. - October 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate Diagnostics" or "the Company") (NASDAQ: AXDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R.

The Law Offices of Frank R. Cruz Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - October 26, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost money in their Accelerate Diagnostics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/axdx.What is this all about?After the market closed on October 21, 2022, Accelerate Diagnostics, Inc. disclosed receiving a request from the U.S.

Accelerate Diagnostics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate Diagnostics" or "the Company") (NASDAQ: AXDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Oct. 26, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) resulting from allegations that Accelerate Diagnostics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Accelerate Diagnostics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Accelerate Diagnostics, Inc. Investors to Inquire About Securities Class Action Investigation - AXDX

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C.

ACCELERATE DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Accelerate Diagnostics, Inc. on Behalf of Accelerate Diagnostics Stockholders and Encourages Investors to Contact the Firm

News for Accelerate Diagnostics Stock (AXDX)